Related Experiment Video
Updated: Jun 1, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Current management of symptomatic intracranial stenosis
Robert A Taylor1, John B Weigele, Scott E Kasner
1Department of Neurology, University of Minnesota, Minneapolis, USA. rataylor@umn.edu
Insights
Intracranial arterial stenosis (IAS) causes strokes, with a high annual risk of recurrence on medical therapy. Endovascular treatment is an option for high-risk patients refractory to antiplatelet agents.
Area of Science:
- Neurology
- Vascular Medicine
- Stroke Research
Background:
- Intracranial arterial stenosis (IAS) contributes significantly to ischemic strokes, particularly in specific populations.
- Patients with IAS face a substantial annual risk of recurrent stroke, with most events occurring within the first year post-event.
- Warfarin offers no advantage over aspirin for preventing recurrent strokes and increases bleeding risks.
Purpose of the Study:
- To review the epidemiology, risk factors, and current treatment strategies for intracranial arterial stenosis.
- To evaluate the role of antiplatelet agents and endovascular therapy in managing symptomatic IAS.
- To identify patient groups at highest risk for recurrent stroke due to IAS.
Main Methods:
- Literature review of studies on intracranial arterial stenosis and ischemic stroke.
- Analysis of risk factors associated with recurrent stroke in IAS patients.
- Evaluation of comparative effectiveness of medical versus endovascular treatments.
Main Results:
- IAS accounts for a notable percentage of ischemic strokes, with higher prevalence in certain demographics.
- High-grade stenosis (≥70%), recent symptom onset, hemodynamic triggers, and female sex are associated with increased recurrent stroke risk.
- Antiplatelet agents are standard medical therapy; endovascular therapy is reserved for refractory high-risk cases.
Conclusions:
- Symptomatic IAS presents a significant risk for recurrent stroke, necessitating effective management strategies.
- Risk stratification is crucial for identifying patients who may benefit from advanced interventions.
- Current guidelines recommend antiplatelet therapy, with endovascular options for select high-risk individuals.
Abstract:
Intracranial arterial stenosis (IAS) is the cause of about 10% of all ischemic strokes in the United States, but may account for about 40% of strokes in some populations. After a stroke or transient ischemic attack due to IAS, patients face a 12% annual risk of recurrent stroke on medical therapy, with most strokes occurring in the first year. Warfarin is no better than aspirin in preventing recurrent strokes but poses a higher risk of serious bleeding and death. Groups with the highest risk of recurrent stroke are those with high-grade (≥ 70%) stenosis, those with recent symptom onset, those with symptoms precipitated by hemodynamic maneuvers, and women. Endovascular treatment of IAS is a rapidly evolving therapeutic option. Antiplatelet agents are currently recommended as the primary treatment for symptomatic IAS, with endovascular therapy reserved for appropriate high-risk cases refractory to medical therapy.
Related Concept Videos
Mitral Stenosis III: Medical Management
Aneurysm III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Aneurysm IV: Nursing Management
Mitral Stenosis IV: Nursing Management
Angle Closure Glaucoma: Treatment
